- Home
- ONCO vs CNSP Comparison
ONCO vs CNSP Comparison
Compare ONCO & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | CNSP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ONCO | CNSP |
|---|---|---|
| Price | $1.85 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.1M | 40.0K |
| Earning Date | 11-13-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $815,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $0.73 |
| 52 Week High | $7.65 | $10.59 |
Technical Indicators
Market Signals| Indicator | ONCO | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 33.31 |
| Support Level | $0.51 | $2.06 |
| Resistance Level | $2.01 | $3.00 |
| Average True Range (ATR) | 0.66 | 0.29 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 22.27 | 11.96 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.